- Company
- Growth hormone Ngenla can be prescribed in general hospitals
- by Eo, Yun-Ho Feb 5, 2024 05:54am
- The growth hormone ‘Ngenla’ can now be prescribed in general hospitals in Korea. According to industry sources, Pfizer Korea’s once-weekly growth hormone Ngenla (somatrogon) has passed the drug committee (DC) reviews of tertiary hospitals including Seoul Asan Medical Center and Sinchon Severance Hospital, as well as medical instituti
- Company
- Enhertu passes the DREC review in KOR
- by Eo, Yun-Ho Feb 5, 2024 05:54am
- ‘Enhertu,’ which had faced difficulties in securing insurance reimbursement listing due to its exceptional effectiveness, has finally received approval from the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA). This approval comes eight months after Enhertu passed the review by t
- Company
- New drugs and biosimilars to compete in the PNH market
- by Chon, Seung-Hyun Feb 2, 2024 12:28pm
- New drugs and biosimilars have shifted the competitive landscape of the treatment market for paroxysmal nocturnal hemoglobinuria (PNH), which Soliris and Ultomiris have previously dominated. PNH is a rare, life-threatening disorder characterized by the destruction of red blood cells in the blood, leading to symptoms such as dark-colored urine an
- Company
- Ildong patents its new GLP-1 drug candidate in CN and JP
- by Lee, Seok-Jun Feb 2, 2024 12:28pm
- Ildong Pharmaceutical(CEO: Woongsup Yun) announced today that it has acquired substance patents for its metabolic disease drug candidate 'ID110521156' in China and Japan. ID110521156 is a new drug candidate being developed through Ildong’s subsidiary Yunovia ID110521156 is a glucagon-like peptide-1 receptor agonist class of medication th
- Company
- Roche’s Crovalimab receives Orphan Drug Designation in KOR
- by Eo, Yun-Ho Feb 2, 2024 12:28pm
- The new PNH drug candidate 'crovalimab' has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety (MFDS) announced so through an orphan drug designation notice on the 1st. Crovalimab, which was discovered by Japanese drugmaker Chugai Pharmaceutical and developed by Roche, is a treatment for paroxysmal nocturn
- Company
- Onureg is now available in general hospitals
- by Eo, Yun-Ho Feb 1, 2024 12:39pm
- General hospitals can now prescribe ‘Onureg,’ an oral acute myeloid leukemia drug. According to industry sources, BMS Pharmaceutical Korea’s Onureg (azacitidine), a new drug for treating acute myeloid leukemia (AML), has recently passed the Drug Committee (DC) of Big 5 tertiary general hospitals, including Samsung Seoul Hospital, Seo
- Company
- SK Biopharm’s new drug tops 500 bln won in US sales
- by Kim, Jin-Gu Feb 1, 2024 12:39pm
- SK Biopharmaceuticals’ Cenobamate, a new epilepsy drug, has generated cumulative sales of 500 billion won in the United States since its launch four years ago. Previously, SK Biopharmaceuticals struggled with operating losses almost every quarter, except for occasional profits from technology exports. However, the company has now turne
- Company
- Oral plaque psoriasis drug Sotyktu in final stages of reimb
- by Kim, Jin-Gu Feb 1, 2024 12:38pm
- The oral plaque psoriasis treatment ‘Sotyktu’ has entered its final stages to reimbursement in Korea. According to Dailypharm’s coverage, BMS Korea accepted the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee’s deliberation results and accepted the condition of setting the price of its TYK2 in
- Company
- HK Inno.N will copromote Xigduo and Sidapvia with AZ
- by Kim, Jin-Gu Feb 1, 2024 12:38pm
- HK Inno.N and AstraZeneca Korea announced on the 31st that they held a signing ceremony at HK Inno.N's Seoul office to mark their strategic collaboration of their diabetes portfolio. Under the agreement, HK Inno.N will jointly market and sell Xigduo (dapagliflozin + metformin) and Sidapvia (dapagliflozin + sitagliptin) with AstraZeneca Ko
- Company
- 13 of Keytruda’s indications await ‘redeliberation’
- by Eo, Yun-Ho Feb 1, 2024 12:38pm
- The first result for the reimbursement for the remaining 13 indications of Keytruda was ultimately a collective ‘hold.’ However, the reimbursement journey for 'Keytruda' has just begun. The Health Insurance Review and Assessment Service held its first Cancer Disease Deliberation Committee meeting of the new year on January 31st and revi
